MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first ...

With barzolvolimab re-treatment, 62% of patients with ColdU and 60% of patients with SD had a complete response at Week 20 in the OLE. These findings are consistent with the complete response rates in ...

MindRank doses first patient in phase III clinical trial of AI-designed oral GLP-1 receptor agonist, MDR-001: Shanghai Saturday, February 28, 2026, 18:00 Hrs [IST] MindRank, a cli ...

President Donald Trump’s 2026 State of the Union address focused on the economy, tax cuts, border security, DHS funding, Iran ...

Explore what is driving progress in neurological biomarker research today, from emerging technologies to clinical translation ...

According to Valuates Reports, The global market for AI in Biotechnology was valued at USD 1033 Million in the year 2024 and ...

Vow ASA ( SSHPF) Q4 2025 Earnings Call February 25, 2026 2:30 AM EST ...

Carvana Co. (NYSE:CVNA) Q4 2025 Earnings Call Transcript February 19, 2026 Operator: Good day, and welcome to the Carvana Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please ...

A new review titled Artificial Intelligence and the Discovery of Antibiotics: Reinventing with Opportunities, Challenges, and ...

Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB February 26, 2026 1:00 PM ...